Victoria Vakiener
Known title: DirectorCIK: 0001826263
Associated companies
Transaction History
| ARWR | ▼ Sell | Open Market | 2,799 | $186K | 12/19/2025 | View on chart |
| ARWR | ▼ Sell | Open Market | 5,281 | $359K | 12/19/2025 | View on chart |
| ARWR | ▼ Sell | Open Market | 1,960 | $134K | 12/19/2025 | View on chart |
| ARWR | ▲ Buy | Grant | 7,819 | $0 | 12/16/2025 | View on chart |
| ARWR | ▲ Buy | Grant | 16,733 | $385K | 12/18/2024 | View on chart |
| ARWR | ▼ Sell | Open Market | 8,994 | $197K | 12/16/2024 | View on chart |
| ARWR | ▼ Sell | Open Market | 1,799 | $42K | 5/2/2024 | View on chart |
| ARWR | ▼ Sell | Open Market | 3,620 | $137K | 1/11/2024 | View on chart |
| ARWR | ▼ Sell | Open Market | 1,100 | $43K | 1/11/2024 | View on chart |
| ARWR | ▲ Buy | Grant | 14,987 | $381K | 12/15/2023 | View on chart |
| ARWR | ▼ Sell | Open Market | 1,550 | $41K | 9/28/2023 | View on chart |
| ARWR | ▼ Sell | Other | 1,764 | $0 | 1/10/2023 | View on chart |
| ARWR | ▲ Buy | Grant | 7,867 | $0 | 1/10/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Arrowhead to Share Alzheimer's Data; Analyst Notes Voucher Value
Arrowhead Pharmaceuticals announced it will host a webinar to present interim clinical data from a Phase 1/2a study of ARO-MAPT for Alzheimer’s disease. Separately, a Seeking Alpha article discussed the financial implications of a $215 million voucher, framing it within the context of fast-follower strategies. The stock is currently trading near its 52-week low, with an RSI of 29.8 indicating oversold conditions.
Arrowhead to Share Alzheimer's Data; Analyst Notes Voucher Value. Arrowhead Pharmaceuticals announced it will host a webinar to present interim clinical data from a Phase 1/2a study of ARO-MAPT for Alzheimer’s disease. Separately, a Seeking Alpha article discussed the financial implications of a $215 million voucher, framing it within the context of fast-follower strategies. The stock is currently trading near its 52-week low, with an RSI of 29.8 indicating oversold conditions.